Recently, pharmacological inhibition of ATGL to restrain basal lipolysis in adipose tissue has been demonstrated to be a potentially powerful therapeutic strategy to combat obesity and associated metabolic disorders (10, 11). The gene discussed is PNPLA2; the disease is obesity due to melanocortin 4 receptor deficiency.